Clinical trials: Metastasis to Brain of Primary Cancer
Brain Cancer
Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis
Magnetic resonance imaging (MRI) is a diagnostic study that makes pictures of organs of the body using magnetic field and radio frequency pulses that can not be felt.
- Trial name
- NCT01974804
- Testing
- MRI
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Breast Cancer Brain Metastasis
A Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug as a Radiosensitizer in Patients With Advanced Breast Cancer Brain Metastasis.
A prospective, multicenter, observational cohort study to evaluate the efficacy and safety of a novel anti-tumor drug as a radiosensitizer in patients with advanced breast cancer brain metastasis.
- Trial name
- NCT06839547
- Testing
- Radiotherapy + Novel Anti-tumor Drug
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
HER2-positive Breast Cancer, Brain Metastases
A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone
This study is being done for the following reasons: The study has two parts. The purpose of the first part (Phase I) of the study is to find out the highest dose of Afatinib that can be given safely with T-DM1.
- Trial name
- HER2BAT (NCT04158947)
- Testing
- Afatinib, T-DM1
- Where
- 4 sites in China
- Volunteers
- 130 people
- Sponsor
- xuexin he
Glioblastoma Multiforme, Brain Neoplasms
Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.
This is a First-In-Human (FIH) study of [68Ga]-FF58 to characterize the imaging properties, safety, biodistribution and dosimetry properties of [68Ga]-FF58 in adults with relapsed or refractory (r/r) glioblastoma multiforme…
- Conditions
- Glioblastoma Multiforme, Brain Neoplasms, Gastroesophageal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT04712721
- Testing
- 68Ga-FF58
- Where
- 2 sites in France, Germany
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Breast Cancer to the Brain
18F-FLT-PET Imaging of the Brain in Patients With Metastatic Breast Cancer to the Brain Treated With Whole Brain Radiation Therapy With or Without Sorafenib: Comparison With MR Imaging of the Brain
The purpose of this study is to compare two different imaging methods to examine the response of brain metastases to WBRT. These two imaging methods will take pictures of the brain using : 1) a positron emission tomography (PET)…
- Trial name
- NCT01621906
- Testing
- 18F-FLT-PET Imaging
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non Small Cell Lung Cancer, NSCLC
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
This is a single arm phase 2 trial is to evaluate the efficacy of SRS plus adagrasib for the treatment of brain metastases for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC).
- Conditions
- Non Small Cell Lung Cancer, NSCLC, KRAS G12C
- Trial name
- NCT06248606
- Testing
- Adagrasib, Stereotactic Radiosurgery
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Ryan Gentzler, MD
HER2-positive Advanced Breast Cancer, Brain Metastases
Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases
A total of 224 subjects of HER2-positive advanced breast cancer with brain metastases are planned to be enrolled. Eligible subjects will be randomly assigned in a 1:1 ratio to the group receiving Trastuzumab Rezetecan combined…
- Conditions
- HER2-positive Advanced Breast Cancer, Brain Metastases, Radiotherapy
- Trial name
- NCT07100600
- Testing
- Trastuzumab Rezetecan, FSRT or WBRT
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer, Estrogen Receptor-Positive
Validity of Brain Metastasis Risk Predictive Model in Hormone Positive Breast Cancer Patients
This study aims to validate a prediction model of brain metastasis risk for females with HR+ breast cancer by using variables collected at diagnosis.
- Trial name
- NCT06729099
- Volunteers
- 128 people
- Sponsor
- Assiut University
Breast Cancer, Brain Metastases
A Study of Pyrotinib Plus Vinorelbine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer
Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER1, HER2 and HER4 receptors. This study is a single-arm, prospective, open label clinical study of pyrotinib plus vinorelbine as the therapy of brain metastases from…
- Trial name
- Pyrotinib (NCT03933982)
- Testing
- Pyrotinib Plus Vinorelbine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese Academy of Medical Sciences
Metastatic Non-Small Cell Lung Cancer
A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases
This is a randomized, Phase II study designed to investigate Nimotuzumab plus whole-brain radiation therapy (WBRT)and to compare it rith WBRT alone in patients with brain metastases from non-small cell lung cancer (NSCLC).
- Trial name
- NCT00872482
- Testing
- nimotuzumab
- Where
- 15 sites in United States, Canada and 3 more
- Volunteers
- 21 people
- Sponsor
- YM BioSciences
Brain Metastasis
Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases
The incidence of brain metastasis of Her2-negative breast cancer is high, which seriously affects the prognosis of patients.The treatment of brain metastasis of Her2-negative breast cancer is still tricky.
- Trial name
- NCT06462079
- Testing
- Sacituzumab Govitecan, Radiotherapy
- Volunteers
- 43 people
- Sponsor
- Guangzhou Medical University
Malignant Primary Brain Tumors, Brain Metastases, Adult
Safety Study of Pritumumab in Brain Cancer
Pritumumab is a human IgG1 kappa antibody that binds to a malignant tumor associated antigen, ecto domain-vimentin (EDV) which is expressed in a variety of tumor cells.
- Trial name
- NCT04396717
- Testing
- Pritumumab
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Nascent Biotech
HER2 Positive Metastatic Breast Cancer
A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer
Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER-1 and HER-2 receptors.This study is a single-arm, prospective, open label clinical study of pyrotinib plus capecitabine as the Therapy of brain metastases from…
- Trial name
- NCT03691051
- Testing
- Pyrotinib plus Capecitabine
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Henan Cancer Hospital
Non-small Cell Lung Carcinoma (NSCLC)
A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases
The purpose of this study is to establish the intracranial efficacy of single agent capmatinib in the population of treatment-naïve or pretreated with one or two prior lines of systemic therapies for advanced stage Non Small-Cell…
- Trial name
- NCT04460729
- Testing
- Capmatinib
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma Multiforme, Brain Metastases
PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404
The purpose of this study is to evaluate diagnostic imaging techniques using 124I-NM404 PET/CT in human brain tumors. This goal will be accomplished by quantifying tumor uptake and determining the optimal PET/CT protocol…
- Trial name
- NCT01540513
- Testing
- NM404
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Wisconsin, Madison
Brain Neoplasms, Brain Cancer
Optimal Planning Target Volume With Stereotactic Radiosurgery
The purpose of this study is to estimate the rate of local control at the treated site of the metastasis as a function of 1mm versus 3mm expansion about the gross tumor volume (GTV).
- Trial name
- NCT01017497
- Testing
- Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Duke University